Use of a chlorhexidine-impregnated patch does not decrease the incidence of bacterial colonization of femoral nerve catheters: a randomized trial
Kristopher M Schroeder, Robert A Jacobs, Christopher Guite, Kyle Gassner, Brooke Anderson, Melanie J Donnelly, Kristopher M Schroeder, Robert A Jacobs, Christopher Guite, Kyle Gassner, Brooke Anderson, Melanie J Donnelly
Abstract
Purpose: Femoral nerve catheter (FNC) insertion is commonly performed for postoperative analgesia following total knee arthroplasty (TKA). A wide range of rates has been reported relating to the bacterial colonization of catheters complicating FNC insertion. The BIOPATCH® is a chlorhexidine (CHG) impregnated patch designed to inhibit bacterial growth for days. The BIOPATCH has proven to be effective at decreasing bacterial colonization in epidural and vascular catheters. We hypothesized that the BIOPATCH would be effective at decreasing the rates of FNC bacterial colonization.
Methods: Following Institutional Review Board approval and written informed consent, 100 patients scheduled for TKA were prospectively enrolled in the study. Patients at elevated risk for infection were excluded from analysis. Femoral nerve catheters were inserted and tunneled under sterile conditions using ultrasound guidance following CHG skin cleansing. Participants were then randomized either to have the BIOPATCH applied to the catheter exit site or not to have the patch applied. All patients received pre/postoperative antibiotic therapy. The FNC tip and catheter exit site were cultured for bacterial growth at the conclusion of therapy.
Results: No differences were observed between groups in regards to catheter exit site. Catheter colonization was observed in three of 48 (6.3%) BIOPATCH patients and two of 47 (4.3%) non-BIOPATCH patients (risk ratio [RR] = 1.5; 95% confidence interval [CI] 0.3 to 8.4; P = 1.0). Colonization of the catheter exit site was observed in 12 BIOPATCH and 14 non-BIOPATCH patients (RR = 0.8; 95% CI 0.4 to 1.6; P = 0.65). Local skin inflammation (non-BIOPATCH 10.6% vs BIOPATCH 2.1%) and colonization of the FNC exit site by more than one type of bacteria trended towards increased values in the non-BIOPATCH group.
Conclusions: The baseline rate of bacterial colonization of FNCs is quite low in the setting of short-term use, CHG skin decontamination, ultrasound guidance, subcutaneous tunneling, and perioperative antibiotic therapy. No benefit was shown by using the BIOPATCH in this patient population. (ClinicalTrials.gov number: NCT01411891).
Figures
Source: PubMed
即将进行的临床试验
-
Wake Forest University Health Sciences尚未招聘
-
West China Second University Hospital尚未招聘睡觉 | 胃腺癌 | 胃食管结合部腺癌 | 病理反应
-
M.D. Anderson Cancer Center招聘中干细胞移植 | 吉西他滨 | 多西紫杉醇 | 卡铂 | 小儿复发 | 前瞻性观察研究 | Melphalan | Refractory Germ美国
-
Washington University School of MedicineCompass Therapeutics尚未招聘
-
AstraZeneca尚未招聘2 型糖尿病美国, 西班牙, 丹麦, 匈牙利, 中国, 台湾, 南非, 希腊, 阿根廷, 日本, 韩国, 土耳其(türkiye)
-
Arcus Biosciences, Inc.尚未招聘
-
West China Second University Hospital尚未招聘胃腺癌 | 情绪困扰 | 胃食管结合部腺癌 | 病理反应
-
West Virginia University尚未招聘
-
AstraZeneca尚未招聘2 型糖尿病美国, 丹麦, 英国, 匈牙利, 巴西, 越南, 马来西亚, 台湾, 中国, 德国, 希腊, 波兰, 乌克兰, 捷克语, 日本, 波多黎各, 阿根廷, 韩国
-
Boehringer Ingelheim尚未招聘肥胖 | 超重美国, 澳大利亚, 英国, 加拿大, 中国, 新西兰, 韩国
